BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 38724991)

  • 1. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
    Puco K; Fagereng GL; Brabrand S; Niehusmann P; Støre Blix E; Samdal Steinskog ES; Haug Å; Fredvik Torkildsen C; Oppedal IA; Meltzer S; Flobak Å; Johansson KAM; Bjørge L; Hjortland GO; Dalhaug A; Lund JÅ; Gilje B; Grønlie Cameron M; Hovland R; Falk RS; Smeland S; Giercksky Russnes HE; Taskén K; Helland Å; ;
    Acta Oncol; 2024 May; 63():379-384. PubMed ID: 38779911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular pathological analysis through the ages].
    Walker M; Mayr EM; Koppermann ML; Terron A; Wagner Y; Kling C; Pfarr N
    Pathologie (Heidelb); 2024 May; 45(3):173-179. PubMed ID: 38619582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).
    Haj Mohammad SF; Timmer HJL; Zeverijn LJ; Geurts BS; Spiekman IAC; Verkerk K; Verbeek FAJ; Verheul HMW; Voest EE; Gelderblom H
    Acta Oncol; 2024 May; 63():368-372. PubMed ID: 38779868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Alterations in Pediatric Solid Tumors.
    Slack JC; Church AJ
    Clin Lab Med; 2024 Jun; 44(2):277-304. PubMed ID: 38821645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pragmatic medicine in solid cancer: a translational alternative to precision medicine.
    Brábek J; Rosel D; Fernandes M
    Onco Targets Ther; 2016; 9():1839-55. PubMed ID: 27103822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New generation of breast cancer clinical trials implementing molecular profiling.
    Zardavas D; Piccart-Gebhart M
    Cancer Biol Med; 2016 Jun; 13(2):226-35. PubMed ID: 27458530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
    Kim SY; Kim JH; Kim TY; Park SR; Yoon S; Lee S; Lee SH; Kim TM; Han SW; Kim HR; Yun H; Lee S; Kim J; Choi YL; Choi KS; Chae H; Ryu H; Lee GW; Zang DY; Ahn JB
    BMC Cancer; 2024 May; 24(1):574. PubMed ID: 38724991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer.
    Behel V; Noronha V; Choughule A; Shetty O; Chandrani P; Kapoor A; Bondili SK; Bajpai J; Kumar R; Pai T; Bal M; Gurav M; Bapat P; Mittal N; Menon S; Patil V; Menon N; Dutt A; Prabhash K
    JCO Glob Oncol; 2022 Jul; 8():e2200030. PubMed ID: 35802838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data.
    Liu R; Rizzo S; Waliany S; Garmhausen MR; Pal N; Huang Z; Chaudhary N; Wang L; Harbron C; Neal J; Copping R; Zou J
    Nat Med; 2022 Aug; 28(8):1656-1661. PubMed ID: 35773542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivering precision oncology to patients with cancer.
    Mateo J; Steuten L; Aftimos P; André F; Davies M; Garralda E; Geissler J; Husereau D; Martinez-Lopez I; Normanno N; Reis-Filho JS; Stefani S; Thomas DM; Westphalen CB; Voest E
    Nat Med; 2022 Apr; 28(4):658-665. PubMed ID: 35440717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer.
    Park S; Ock CY; Kim H; Pereira S; Park S; Ma M; Choi S; Kim S; Shin S; Aum BJ; Paeng K; Yoo D; Cha H; Park S; Suh KJ; Jung HA; Kim SH; Kim YJ; Sun JM; Chung JH; Ahn JS; Ahn MJ; Lee JS; Park K; Song SY; Bang YJ; Choi YL; Mok TS; Lee SH
    J Clin Oncol; 2022 Jun; 40(17):1916-1928. PubMed ID: 35271299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.
    Yoon S; Kim M; Hong YS; Kim HS; Kim ST; Kim J; Yun H; Yoo C; Ahn HK; Kim HS; Lee IH; Kim IH; Park I; Jeong JH; Cheon J; Kim JW; Yun J; Lim SM; Cha Y; Jang SJ; Zang DY; Kim TW; Kang JH; Kim JH
    Cancer Res Treat; 2022 Jan; 54(1):1-9. PubMed ID: 34902959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.
    Larson KL; Huang B; Weiss HL; Hull P; Westgate PM; Miller RW; Arnold SM; Kolesar JM
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34632252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
    Flaherty KT; Gray RJ; Chen AP; Li S; McShane LM; Patton D; Hamilton SR; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Harris LN; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Zwiebel JA; Rubinstein LV; Little RF; Arteaga CL; Comis R; Abrams JS; O'Dwyer PJ; Conley BA;
    J Clin Oncol; 2020 Nov; 38(33):3883-3894. PubMed ID: 33048619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Tumor Boards in Clinical Practice.
    Luchini C; Lawlor RT; Milella M; Scarpa A
    Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Snapshot: Trial Types in Precision Medicine.
    Dickson D; Johnson J; Bergan R; Owens R; Subbiah V; Kurzrock R
    Cell; 2020 Apr; 181(1):208-208.e1. PubMed ID: 32243791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine.
    Dickson D; Johnson J; Bergan R; Owens R; Subbiah V; Kurzrock R
    Cell; 2020 Jan; 180(1):9-14. PubMed ID: 31951522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
    van der Velden DL; Hoes LR; van der Wijngaart H; van Berge Henegouwen JM; van Werkhoven E; Roepman P; Schilsky RL; de Leng WWJ; Huitema ADR; Nuijen B; Nederlof PM; van Herpen CML; de Groot DJA; Devriese LA; Hoeben A; de Jonge MJA; Chalabi M; Smit EF; de Langen AJ; Mehra N; Labots M; Kapiteijn E; Sleijfer S; Cuppen E; Verheul HMW; Gelderblom H; Voest EE
    Nature; 2019 Oct; 574(7776):127-131. PubMed ID: 31570881
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.